Oral News and Research

RSS

Exelixis reports data from cabozantinib phase 3 trial on MTC

Exelixis, Inc. today reported data from the phase 3 pivotal trial of cabozantinib in patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).

5 Jun 2012

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

OncoGenex Pharmaceuticals, Inc. announced today data from a Phase 2 study of its investigational compound OGX-427 in chemotherapy-naive metastatic castration resistant prostate cancer (mCRPC) patients will be presented during an oral presentation at the 2012 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday, June 5.

5 Jun 2012

Preliminary results from Incyte’s INCB024360 Phase I trial on solid tumors

Incyte Corporation presented preliminary results today from the ongoing Phase I clinical trial for its oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB024360, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

5 Jun 2012

Takeda announces updated results from orteronel phase 2 study on nmCRPC

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced updated results from a phase 2 study of orteronel, a selective oral 17,20 lyase inhibitor, dosed without prednisone in patients with non-metastatic castration resistant prostate cancer (nmCRPC) and rising prostate-specific antigen.

5 Jun 2012

$Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML$

Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML

Astellas Pharma Inc. and Ambit Biosciences Corporation today announced the initiation of a Phase 2b open-label clinical trial of quizartinib as monotherapy in patients with relapsed and refractory acute myeloid leukemia (AML) with FLT3-ITD mutations.

5 Jun 2012

Prisoners need education on the appropriate use of topical antibiotic products

Prisoners need education on the appropriate use of topical antibiotic products, according to a study released today at the 39th Annual Educational Conference and International Meeting of the Association for Professionals in Infection Control and Epidemiology.

4 Jun 2012

Exelixis reports positive interim data from cabozantinib phase 2 trial on HCC

Exelixis, Inc. today reported positive updated interim data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.

4 Jun 2012

Onyx announces data from regorafenib Phase 3 trial on GIST

Onyx Pharmaceuticals today announced data from the Phase 3 GRID (GIST – Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib.

4 Jun 2012

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Oncothyreon Inc. today announced that data from two clinical trials of PX-866, a pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

4 Jun 2012

CTI acquires world-wide rights to S*BIO’s pacritinib

Cell Therapeutics, Inc., announced today that it has completed its acquisition gaining world-wide rights to S*BIO Pte Ltd.'s pacritinib.

4 Jun 2012

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

4 Jun 2012

Interim results from Bristol-Myers Squibb’s BMS-936558 Phase 1 study on NSCLC, MM and RCC

Bristol-Myers Squibb Company today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with previously-treated non small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC).

4 Jun 2012

New evidence of important role of next-generation sequencing in cancer treatment

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced results from two studies using next-generation sequencing (NGS) to provide actionable information about genomic tumor alterations in individual patients' cancers across all solid tumor types.

2 Jun 2012

New molecular test panel to enhance reliability of thyroid biopsy testing

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced a new molecular test panel designed to help physicians determine if a thyroid gland is cancerous and requires surgical removal.

From Quest Diagnostics 2 Jun 2012

ZYTIGA Phase 3 study for metastatic prostate cancer presented at 48th ASCO

New data presented this weekend at the 48th annual meeting of the American Society of Clinical Oncology (ASCO) showed ZYTIGA (abiraterone acetate) may prove to be an important new treatment option for metastatic prostate cancer patients prior to receiving chemotherapy.

2 Jun 2012

Cera announces new citrus ready-to-drink oral rehydration solution

Cera Products is proud to announce its new CeraLyte-70 Citrus Ready to Drink in a 500 ml environmentally green container with a re-closeable top and a long shelf-life. No mixing is needed, saving health care staff time when fast patient hydration is needed.

2 Jun 2012

New medication proves effective in slowing the spread of metastatic prostate cancer

A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results.

2 Jun 2012

ENTA announces availability of first non-invasive oral cancer prevention test

Oral cancer is one of the few cancers still on the rise, claiming the lives of as many Americans as melanoma and has shown a recent increase in young, non-smokers. The important news is that oral cancer can now be prevented.

2 Jun 2012

Study provides novel mechanism of action of anti-cancer compound: perifosine

Aeterna Zentaris Inc. today announced that an article published in the May 2012 issue of Plos One, outlines a novel mechanism of action of the Company's oral anti-cancer compound, perifosine, which could provide a rationale for a novel approach to the treatment of Malignant Pleural Mesothelioma (MMe), an aggressive type of cancer associated with exposure to asbestos.

2 Jun 2012

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

Bringing together international experts with the latest technologies and pioneering research, Montefiore Einstein Center for Cancer Care, in collaboration with the National Cancer Institute-designated Albert Einstein Cancer Center, advances the front lines of prevention, diagnosis and treatment of rare and common cancers.

2 Jun 2012